Clinical data | |
---|---|
Other names | DU-28,853; DU-28853 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C12H16N2O2 |
Molar mass | 220.272 g·mol−1 |
3D model (JSmol) | |
| |
|
Eltoprazine (developmental code name DU-28,853) is a serotonergic drug of the phenylpiperazine class which is described as a serenic or antiaggressive agent.[1][2][3] It acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor.[3][4] The drug is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan. Eltoprazine is or was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of February 2022.[1] It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued.[1] Eltoprazine was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay.[1]